User: Guest  Login
Title:

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.

Document type:
Article; Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Author(s):
Goldman, Jason D; Lye, David C B; Hui, David S; Marks, Kristen M; Bruno, Raffaele; Montejano, Rocio; Spinner, Christoph D; Galli, Massimo; Ahn, Mi-Young; Nahass, Ronald G; Chen, Yao-Shen; SenGupta, Devi; Hyland, Robert H; Osinusi, Anu O; Cao, Huyen; Blair, Christiana; Wei, Xuelian; Gaggar, Anuj; Brainard, Diana M; Towner, William J; Muñoz, Jose; Mullane, Kathleen M; Marty, Francisco M; Tashima, Karen T; Diaz, George; Subramanian, Aruna
Abstract:
BACKGROUND: Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro and efficacy in animal models of coronavirus disease 2019 (Covid-19). METHODS: We conducted a randomized, open-label, phase 3 trial involving hospitalized patients with confirmed SARS-CoV-2 infection, oxygen saturation of 94% or less while they were breathing ambient air, and radiologic evidence of pneumonia. Patients were randomly assigned in a 1:1 ratio to receive intravenous remdesivir for either 5 d...     »
Journal title abbreviation:
N Engl J Med
Year:
2020
Journal volume:
383
Journal issue:
19
Pages contribution:
1827-1837
Fulltext / DOI:
doi:10.1056/NEJMoa2015301
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/32459919
Print-ISSN:
0028-4793
TUM Institution:
II. Medizinische Klinik und Poliklinik (Gastroenterologie)
 BibTeX